Adverse effect of unsp fibrinolysis-affecting drugs, subs

This code signifies a patient experiencing an unintended, undesirable reaction to a fibrinolysis-affecting drug, where the specific drug is not documented. This adverse effect is being addressed during a follow-up visit after initial treatment for the reaction. Fibrinolysis-affecting drugs include agents that promote or inhibit the breakdown of blood clots.

Apply this code when a patient presents for ongoing management or evaluation of an adverse effect from an unidentifiable fibrinolysis-affecting medication. This is appropriate for subsequent encounters related to the adverse event, such as follow-up appointments for monitoring symptoms or adjusting treatment. It should be used when the initial acute phase of treatment for the adverse effect has concluded.

• Always sequence this code after the code(s) for the specific manifestation of the adverse effect.
• Ensure documentation clearly indicates the encounter is for follow-up care related to the adverse effect, not the initial treatment.
• If the specific fibrinolysis-affecting drug is known, a more specific code from the T45.6 category should be used instead.